Ruixun Bio

elsewhere's corpus does not cover Ruixun Bio as a subject in its own right. The retrieved material only mentions the company in passing as a ZhenFund angel portfolio project—appearing in Z News roundups from late 2024 and early 2025 that note its digital PCR technology and a C2 strategic financing round—without providing details on its founding, team, technology platform, or business focus . The name similarity with "瑞瞳生物" (Rayton Bio / Ruitong Bio), a Shenzhen-based ocular drug-delivery company founded in 2021 with an iSus® sustained-release platform , appears to be a distinct entity. No substantive profile of Ruixun Bio itself is available in elsewhere's current corpus.